Kalliopé advised Kurma Partners, Eurazeo and Aurinvest on the sale of their stake in PathoQuest to Charles River Laboratories.
Founded in 2010, PathoQuest is a pioneer and global leader in next-generation sequencing-based biosafety testing. The company develops innovative biosafety testing solutions for biotherapies, vaccines and advanced biological products.
Originally spun out from Institut Pasteur, PathoQuest has been backed since its early days by Kurma Partners, later joined by Eurazeo and Aurinvest. The transaction represents a new strategic milestone in the company’s development.
The Kalliopé team advising on the corporate/M&A aspects of the transaction comprised Alexia Berbain-Faguer (partner) and Ava Sereshki (associate).
Photo credit: Marvin Radke
